Elix and University of Vienna Enter Joint Research Agreement for AI Drug Discovery

Japanese AI drug discovery firm Elix has signed a joint research agreement with the University of Vienna. The collaboration will combine Elix's AI platform for molecular generation with the university's expertise in NMR spectroscopy to design novel compounds against "undruggable" protein targets implicated in cancer.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.